COMP <GO>
QTTB vs ABBV // EV/EBITDA & P/E VALUATION
Q32 Bio Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: QTTB 6
— ABBV 5
▲ EV/EBITDA & P/E VALUATION LEADER: QTTB
LAST: $8.87 (-2.10%) • MKT CAP: $264.1M
valuation
12.8x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QTTB VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QTTB | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 29.00% | +56.00 | QTTB | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 12.8x | 33.3x | -20.50 | QTTB | /valuation <GO> |
| Free Cash Flow Yield | -12.70% | 3.47% | -16.17 | ABBV | /fcf-yield <GO> |
| Operating Margin | 31.50% | 24.60% | +6.90 | QTTB | /operating-margins <GO> |
| Net Profit Margin | 55.50% | 6.90% | +48.60 | QTTB | /net-margins <GO> |
| Revenue Growth (YoY) | — | 8.60% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.99 | 5.33 | +0.66 | QTTB | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.1 | 65.1 | -16.98 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.3x | 113.1x | -104.80 | QTTB | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $264.1M | $513.86B | -$513.60B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QTTB REV | ABBV REV | QTTB GROSS % | ABBV GROSS % | QTTB FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $53.7M | $61.16B | — | 70.2% | -$33.5M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$67.8M | $17.83B |
| FY 2023 | $1.2M | $54.32B | — | — | -$18.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QTTB // BETA —
ABBV // BETA 1.15